Market Access, Pharmaceutical Pricing, and Healthcare Costs

Thomas, Dixon; John, Denny; Ashoush, Nermeen; Lega, Federico; Li, Hong

doi:10.1016/b978-0-12-814276-9.00017-9

Cited by 2 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 , 59 In many countries, Pharmacoeconomic Evaluations (PEs) plays an increasingly important role in informing clinical development and market access decisions of new innovative medicines. 60 , 61 Since there is a lack of information on whether new considerations are to be included in the PE of I-O drugs, a search of the literature was performed to identify all peer-reviewed published articles on PEs of marketed ICI therapies (ipilimumab, pembrolizumab, and nivolumab) and comment on the modes of evaluation. The literature search identified only one cost-effectiveness study of ipilimumab.…”

Section: Considerations For Economic Evaluationmentioning

confidence: 99%

Immuno-Oncology Medicines: Policy Implications and Economic Considerations

et al. 2019

View full text Add to dashboard Cite

Significant progress has taken place in the field of cancer immunotherapy in recent years. Cancer immunotherapy, particularly immune checkpoint inhibitors, have shown rather dramatic results and are believed to have completely transformed the field of oncology. However, these transformational therapies are more expensive than previous cancer therapies. As more cancer immunotherapy agents are being developed, with some already being marketed, it is important to consider how economic constraints will shape health policy and value assessment related to these agents. A number of strategies have been suggested to alleviate the price burden and the ensuing concerns about the sustainability of publicly funded healthcare systems. Among these strategies, value-based pricing (VBP) for innovative drugs dominates the headlines in the field of oncology. The specifics of how VBP may be implemented in the United States is still unclear. Nonetheless, policy reform and economic considerations will have to be incorporated into the planning of VBP. The objective of this paper is multifold: (i) to identify the factors affecting the impact of cancer immunotherapy on healthcare cost; (ii) to critically appraise current approaches used to assess the value of novel cancer therapies; (iii) to assess the methodological challenges associated with the economic evaluation of cancer immunotherapy. As the health care system in the U.S transitions toward a value-based model, the need for a formal value assessment framework is warranted in cancer immunotherapy. Article Type: Review

show abstract

Section: Considerations For Economic Evaluationmentioning

confidence: 99%

Immuno-Oncology Medicines: Policy Implications and Economic Considerations

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In health care, MA has been defined as “the set of strategies, activities and processes that pharmaceutical and biomedical companies develop to ensure that their products are made available and adequately priced in a specific health-care system” (Thomas et al , 2018).…”

Section: Market Accessmentioning

confidence: 99%

“…Past research has acknowledged that industrial marketing plays a pivotal role in the success (or unsuccess) of the adoption and diffusion of innovations within B2B networks (Frambach, 1993; Makkonen and Johnston, 2014; Woodside and Biemans, 2005). In the health-care sector, these activities are usually included in the MA strategy implemented by pharmaceutical and MedTech companies, which defines the set of activities and processes to develop to ensure that new products (drugs, medical devices, other technologies) are made available and adequately priced in a specific health-care system (Thomas et al , 2018).…”

Section: Introductionmentioning

confidence: 99%

“…This is not just due to the before mentioned current technological and economic conjuncture but also to the need to develop (with and for) and subsequently demonstrate the value of new products to a plurality of interlocutors (Guercini et al , 2020; Kumar et al , 2014). These include a new and diverse set of stakeholders that have emerged over the past years and gained dominant positions, generating the need for a new “share of voice” (Thomas et al , 2018). In this context, MA requires good and deeper interactions with Key Opinion Leader (KOL) clinicians, agencies/authorities, hospital managers, pharmacists, leaders of governing authorities, Health Technology Assessment (HTA) Committees, insurance managers, doctors involved in clinical governance, patient associations and influential associations (Thomas et al , 2018).…”

Section: Introductionmentioning

confidence: 99%

“…These include a new and diverse set of stakeholders that have emerged over the past years and gained dominant positions, generating the need for a new “share of voice” (Thomas et al , 2018). In this context, MA requires good and deeper interactions with Key Opinion Leader (KOL) clinicians, agencies/authorities, hospital managers, pharmacists, leaders of governing authorities, Health Technology Assessment (HTA) Committees, insurance managers, doctors involved in clinical governance, patient associations and influential associations (Thomas et al , 2018). Over seeking the involvement of this intertwined and interlocked network of stakeholders, MA should be strictly integrated with research and development (R&D), commercial and marketing activities establishing an inter-functional strategy to favour the access, adoption and recognition of the value of new products in the health-care sector (Guercini et al , 2020; Kumar et al , 2014; McClearn and Croisier, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The market access of innovation in health care: insights from EC-funded research

Lettieri

Marone

Spezia

et al. 2022

JBIM

View full text Add to dashboard Cite

Purpose This study aims to offer novel insights on how industrial marketing might contribute to bringing innovations to market in the peculiar case of health care. This study aims at shedding first light on how the alignment between dissemination and exploitation activities might contribute to bringing to market innovations developed by public–private partnerships funded by the European Commission (EC). Design/methodology/approach The theoretical development comes from an inductive research design based on the 42-month pan-European H2020 research project NESTORE aimed at developing an integrated portfolio of innovations for the healthy aging of European citizens. Findings This study advances the theory and practice of industrial marketing in health care by conceptualizing an actionable method to align dissemination and exploitation activities within EC-funded projects, facilitating that innovations will go to market. The method is composed of five phases. First, an external analysis to define market opportunities and users’/stakeholders’ needs. Second, an internal analysis to identify the most promising exploitable outputs. Third, scenarios crystallization to define the most suitable scenarios (business models) to bring the selected exploitable outputs to market. Fourth, exploitation and dissemination alignment through the identification and involvement of the most relevant stakeholders. Fifth, scenario refinement and business plan. Originality/value This study is relevant because many EC-funded projects still fail to move innovations from labs to market, thus limiting the benefits for the European citizens and the competitiveness of Europe with respect to the USA and China. Although this relevance, past studies overlooked the peculiar context of EC-funded innovation projects, privileging pharmaceutical and biomedical companies. This study advance theory and practice of industrial marketing in health care.

show abstract

Market Access, Pharmaceutical Pricing, and Healthcare Costs

Cited by 2 publications

References 23 publications

Immuno-Oncology Medicines: Policy Implications and Economic Considerations

Immuno-Oncology Medicines: Policy Implications and Economic Considerations

The market access of innovation in health care: insights from EC-funded research

Contact Info

Product

Resources

About